Free Delivery Over $100
|
|
|||
|
||||
OverviewThis comprehensive volume covers radiopharmaceuticals developed for pathway-directed systems in imaging and theranostic applications. We now are at the cutting edge of providing personalized treatment with increased use in oncology of these new radiopharmaceuticals. Trends in high-resolution instrumentation development, quality assurance systems and regulatory compliance for radiopharmaceuticals, clinical evaluation of radiopharmaceuticals, and benefits and pitfalls of the current clinical FDG PET are discussed. Radiopharmaceuticals are used for diagnosis of diseases of the central nervous and cardiovascular systems and for staging, restaging, and treatment planning for cancers. Nuclear biomarkers allow precise measurement of molecular pathways on a whole-body image upon administration of functional radiolabeled agents, and nuclear imaging agentshave potential use in patient selection, pharmacokinetic, dosage-finding, and proof-of-concept studies. Nuclear imaging agents and hybrid instrumentation also provide sensitive and specific answers for differential responsiveness in therapeutic outcome. This book serves as a reference for moving the discovery and development of radiopharmaceuticals from the workbench to clinical applications. It thus benefits not only clinicians but also translational research scientists—molecular biologists, chemists, imaging scientists, pharmaceutical developers, physicists, and support staff. Full Product DetailsAuthor: Tomio Inoue , David Yang , Gang HuangPublisher: Springer Verlag, Singapore Imprint: Springer Verlag, Singapore Edition: 1st ed. 2017 Weight: 5.078kg ISBN: 9789811033483ISBN 10: 981103348 Pages: 243 Publication Date: 10 March 2017 Audience: Professional and scholarly , Professional & Vocational Format: Hardback Publisher's Status: Active Availability: Manufactured on demand  We will order this item for you from a manufactured on demand supplier. Table of ContentsReviewsAuthor InformationDr. Tomio Inoue President, Yokohama City University Medical Center Dr. David J. Yang Professor and Section Chief, Radiotheranostic Section, Department of Cancer System Imaging, Division of Diagnostic Imaging, MD Anderson Cancer Center, Consultant and Professor at The University of Tennessee Health Science Center, Vice-president for Vyripharm Biopharmaceuticals Dr. Gang Huang Chairman, Institute of Nuclear Medicine, Shanghai JiaoTong University School of Medicine Tab Content 6Author Website:Countries AvailableAll regions |
||||
